Available in 10 mg and 30 mg vials, in lyophilized form.
Tirzepatide is a synthetic 39-amino-acid peptide engineered as a dual agonist at the GIP and GLP-1 receptors. It is based on the native GIP sequence with modifications conferring GLP-1 receptor activity, and carries a fatty diacid moiety that extends its circulating half-life.
Its hybrid architecture makes it a reference compound for research into dual incretin pathway signalling. Published studies examine relative potency at each receptor, biased agonism and beta-arrestin recruitment, and downstream metabolic endpoints in cell and animal models.
Areas of published research
- Glucose tolerance and insulin sensitivity endpoints in db/db and diet-induced obese rodent models
- Body weight and food intake measures in preclinical study designs
- Relative potency at GIP and GLP-1 receptors, and biased agonism and beta-arrestin recruitment in cell assays
- Comparative work against single-receptor GLP-1 agonists
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.


Reviews
There are no reviews yet.